Phenobarbital (PB)-induced changes in blood coagulationrelated parameters in pregnant rats, lactating rats and pups

Masahiro Mochizuki1, Satomi Shimizu, Yuri Kidokoro

  • 1Bozo Research Center Inc. Shizuoka, Japan. mochizuki@bozo.co.jp

Insights

Phenobarbital (PB) administration prolonged blood clotting times in lactating rats and their pups. Vitamin K2 (VK2) improved clotting in pups but not dams, indicating differential effects.

Area of Science:

  • Pharmacology
  • Toxicology
  • Biochemistry

Background:

  • Phenobarbital (PB) is known to affect liver enzymes and drug metabolism.
  • The impact of PB on blood coagulation, particularly during pregnancy and lactation, requires further investigation.
  • Understanding these effects is crucial for assessing risks in vulnerable populations.

Purpose of the Study:

  • To investigate the effects of repeated phenobarbital (PB) administration on blood coagulation parameters in non-pregnant, pregnant, and lactating rats.
  • To evaluate the impact of PB exposure on coagulation in pups born to treated dams.
  • To assess the efficacy of vitamin K2 (VK2) in mitigating PB-induced coagulation changes.

Main Methods:

  • Rats (non-pregnant, pregnant, lactating) received daily oral doses of PB (80 mg/kg) for 7 days.
  • Blood samples were collected for coagulation tests (PT, APTT) and anti-thrombin III (ATIII) concentration.
  • Coagulation parameters were also assessed in pups born to PB-treated lactating dams.
  • Co-administration of PB and VK2 was used to evaluate VK2's protective effects.

Main Results:

  • PB increased liver weight and hepatic cytochrome P450 content in treated rats.
  • Lactating rats showed prolonged activated partial thromboplastin time (APTT) and increased anti-thrombin III (ATIII) concentration.
  • Pups exhibited prolonged prothrombin time (PT) and APTT, with decreased factors VII and IX activities.
  • Vitamin K2 (VK2) improved PB-induced coagulation prolongation in pups but not in dams.

Conclusions:

  • Repeated PB administration significantly alters blood coagulation in lactating rats and their offspring.
  • PB exposure during lactation poses a risk for coagulation disturbances in both dams and pups.
  • Vitamin K2 (VK2) shows potential therapeutic benefit for PB-induced coagulopathy in pups, but not in dams.

Related Concept Videos

Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems01:19

Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...